PET clinicsPub Date : 2025-04-07DOI: 10.1016/j.cpet.2024.06.003
Lisa Bodei, Vetri Sudar Jayaprakasam, Bernadette Zhi Ying Wong, Carina Mari Aparici
{"title":"Neuroendocrine Tumors: Beta Labeled Radiopeptides.","authors":"Lisa Bodei, Vetri Sudar Jayaprakasam, Bernadette Zhi Ying Wong, Carina Mari Aparici","doi":"10.1016/j.cpet.2024.06.003","DOIUrl":"https://doi.org/10.1016/j.cpet.2024.06.003","url":null,"abstract":"<p><p>Peptide receptor radionuclide therapy (PRRT) consists of administrating a radiolabeled octreotide derivative that targets somatostatin receptors present on the cell membrane of neuroendocrine tumor cells. Although PRRT was initially performed with 90Y-peptides, currently 177Lu-peptides represent the predominant form of treatment. PRRT results in significant tumor and symptomatic control in patients. Like with other available systemic therapies, responses are relatively short-lived. Several new peptides and strategies to improve the efficacy and tolerability of PRRT have been proposed. A critical step is individualizing treatments based on specific dosimetric estimates for the tumor and normal organs, and determining tissue radiosensitivity.</p>","PeriodicalId":94168,"journal":{"name":"PET clinics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143813267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}